Lajos Pusztai

Yale University

Full Professor(heuristic)

Breast Cancer Treatment Studies · Cancer Research

Compare more Cancer Research professors.

h-index114
i10-index450
Publications1,394
Citations69,663

Grants

4 total · 2 active

NIH #P30CA016359

Genomics, Genetics and Epigenetics Research Program

Active
Amount
<$100K
Period
1997-07-01 → 2029-07-31
PIs
1

NIH #R01CA286128

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Active
Amount
$600K–$700K
Period
2023-12-14 → 2028-11-30
PIs
2

Awarded at ARIZONA STATE UNIVERSITY-TEMPE CAMPUS

NIH #R01CA219647

Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome

Amount
$500K–$600K
Period
2017-09-01 → 2021-07-31
PIs
1

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

4 total · 2 active

NIH #P30CA016359

Genomics, Genetics and Epigenetics Research Program

Active
Amount
<$100K
Period
1997-07-01 → 2029-07-31
PIs
1

NIH #R01CA286128

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Active
Amount
$600K–$700K
Period
2023-12-14 → 2028-11-30
PIs
2

Awarded at ARIZONA STATE UNIVERSITY-TEMPE CAMPUS

NIH #R01CA219647

Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome

Amount
$500K–$600K
Period
2017-09-01 → 2021-07-31
PIs
1

NIH #R01CA106290

Preoperative chemotherapy for breast cancer

Amount
$100K–$200K
Period
2005-04-14 → 2008-03-31
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Recent Public Signals

  1. New preprint: Distillation enables scalable high-fidelity virtual screening across ultra-large chemical libraries2026-07-03
  2. New paper: Data from The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets2026-07-01
  3. New NIH award: Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer2023-12-14

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-30

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0001-9632-6686

Professor Insights

Career Trajectory